A5063021266- Dermatology and Skin Diseases
- Allergic Rhinitis and Sensitization
- Asthma and respiratory diseases
- Autoimmune Bullous Skin Diseases
- Urticaria and Related Conditions
- Coagulation, Bradykinin, Polyphosphates, and Angioedema
- Delphi Technique in Research
- Contact Dermatitis and Allergies
- Food Allergy and Anaphylaxis Research
- Cutaneous lymphoproliferative disorders research
- Drug-Induced Adverse Reactions
- Cancer and Skin Lesions
- Skin Protection and Aging
- Nonmelanoma Skin Cancer Studies
- Platelet Disorders and Treatments
- Fungal Infections and Studies
- Cutaneous Melanoma Detection and Management
- Acne and Rosacea Treatments and Effects
- Blood Pressure and Hypertension Studies
- Eosinophilic Disorders and Syndromes
- Chronic Lymphocytic Leukemia Research
- Health and Medical Studies
- Hidradenitis Suppurativa and Treatments
- Fibromyalgia and Chronic Fatigue Syndrome Research
- Microscopic Colitis
Tel Aviv University
2013-2024
Rabin Medical Center
2013-2024
Schneider Children's Medical Center
2022
AbbVie (United States)
2022
Misgav Ladach
2022
Universidad de Salamanca
2022
Oregon Health & Science University
2014-2016
Technion – Israel Institute of Technology
2008
Emek Medical Center
1989-1994
Journal Article What the Eczema Area and Severity Index score tells us about severity of atopic dermatitis: an interpretability study Get access Y.A. Leshem, Leshem Department Dermatology Oregon Health & Science University 3303 SW Bond Avenue Portland OR 97239‐4501 U.S.A Search for other works by this author on: Oxford Academic Google Scholar T. Hajar, Hajar J.M. Hanifin, Hanifin E.L. Simpson Correspondence Eric L. Simpson. E‐mail: simpsone@ohsu.edu British Dermatology, Volume 172, Issue 5,...
Core outcome sets are critically important outcomes that should be measured in clinical trials. Their absence atopic dermatitis is a form of research waste and impedes combining evidence to inform patient care. Here, we articulate the rationale for core review work international Harmonising Outcome Measures Eczema group from its inception Munich, 2010. We describe domain determination (what measured), instrument selection (how domains culminating complete measurement set Tokyo, 2019. Using...
This is the report from fifth meeting of Harmonising Outcome Measures for Eczema initiative (HOME V). The was held on 12–14 June 2017 in Nantes, France, with 81 participants. main aims were (i) to achieve consensus over definition core domain long‐term control and how measure it (ii) prioritize future areas research measurement quality life (QoL) children. Moderated whole‐group small‐group discussions informed by presentations qualitative studies, systematic reviews validation studies....
This article is a report of the fourth meeting Harmonising Outcome Measures for Eczema (HOME) initiative held in Malmö, Sweden on 23–24 April 2015 (HOME IV). The aim was to achieve consensus over preferred outcome instruments measuring patient‐reported symptoms and quality life HOME core set atopic eczema (AE). Following presentations, which included data from systematic reviews, discussions were mixture whole group small discussions. Small groups allocated priori ensure representation...
Aim To identify risk factors for the development of dupilumab-induced ocular surface disease (DIOSD) in adult patients with atopic dermatitis (AD) and describe outcomes treatment. Methods A retrospective institutional cohort study performed at Rabin Medical Center, Petach Tikva, Israel. Adult AD who received dupilumab from March 2018 to June 2019 were included. Demographics, severity scores, blood IgE levels, previous keratoconjunctivitis (AKC), dermatological response dupilumab,...
Abstract Background Conjunctivitis is common in patients with atopic dermatitis ( AD ) general and a commonly reported adverse event clinical trials dupilumab. Objective To survey opinions experience about conjunctivitis occurring , including those during dupilumab treatment group of experts from the International Eczema Council IEC ). Methods Electronic in‐person discussion management strategies. Results Forty‐six (53.5%) members 19 countries responded to survey. Consensus was reached for...
Measuring outcomes in clinical practice can aid patient care, quality improvement, and real-world evidence generation. The Harmonising Outcome Measures for Eczema (HOME) Clinical Practice initiative is developing a list of validated, feasible instruments to measure atopic eczema care. Prior work identified symptoms long-term control as the most important domains practice. Patient-Oriented Measure (POEM) Scoring Atopic Dermatitis Index (PO-SCORAD) were recommended by consensus practice, but...
Janus kinase inhibitors (JAKinibs) have the potential to dramatically alter landscape of atopic dermatitis (AD) management due their promising efficacy results from phase 3 trials and rapid onset action. However, JAKinibs are not without risk, use is appropriate for all AD patients, making this a medication class that dermatologists should understand consider when treating patients with moderate-to-severe AD.
<h3>Importance</h3> <i>Pneumocystis</i>pneumonia (PCP) is a potentially lethal opportunistic infection that primary prophylaxis can help prevent. The risk of prophylactic therapy must be weighed against the incidence PCP in patient population. Prophylaxis most frequently involves trimethoprim-sulfamethoxazole, with second-line therapies, including atovaquone, dapsone, and pentamide. indication for immunocompromised patients without HIV less well defined. Previously, an at least 3.5% has been...
Real-world data on the epidemiology and economic burden of atopic dermatitis (AD) are limited. Here we describe AD using electronic healthcare from Israel. A retrospective study was performed Maccabi Healthcare Services database. incidence in 2008–2017 point prevalence (ADprev) 31 December 2017 were described diagnosis codes for overall patients, sex age subgroups. For ADprev, severity defined recently dispensed treatments AD. Annual resource utilization prevalent patients compared with...
Abstract Background Pemphigus is an autoimmune blistering disease affecting the skin and mucosa, which mostly in anecdotal reports has been associated with several diseases. Objective The aim of this study was to assess frequency diseases a large group patients pemphigus their first‐degree relatives. Methods One hundred ten were interviewed for existence various Patients’ sera examined presence autoantibodies. 969 relatives assessed via questionnaires. Results Seven 110 (6.3%) had concurrent...